The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Kun-Chieh Chen, Chia-Hung Hsu, Kang-Yi Su, Jeremy J. W. Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, Gee-Chen Chang
Cancer Res Treat. 2018;50(4):1294-1303.   Published online 2018 Jan 4     DOI: https://doi.org/10.4143/crt.2017.512
Citations to this article as recorded by Crossref logo
Association of hOGG1 ‐Cys variants with occurrence of p53 and EGFR deletion mutations in non‐small c
Ming‐Jenn Chen, Ching‐Ju Shen, Lee Wang, Po‐Ming Chen, Chih‐Yi Chen, Huei Lee
Thoracic Cancer.2021; 12(4): 534.     CrossRef
The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
Wen-Chien Cheng, Te-Chun Hsia, Chih-Yen Tu, Hung-Jen Chen
OncoTargets and Therapy.2021; Volume 13: 13425.     CrossRef
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
Alessandro Dal Maso, Martina Lorenzi, Elisa Roca, Sara Pilotto, Marianna Macerelli, Valentina Polo, Fabiana Letizia Cecere, Alessandro Del Conte, Giorgia Nardo, Vanessa Buoro, Daniela Scattolin, Sara Monteverdi, Loredana Urso, Elisabetta Zulato, Stefano F
Clinical Lung Cancer.2020; 21(1): 1.     CrossRef
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Tzu-Hsiu Tsai, Chia-Lin Hsu, Kang-Yi Su, Yih-Leong Chang, Chen-Tu Wu, Chia-Chi Hsu, Bin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, Chia-Chi Lin, Jin-Yuan Shih, James C.-H. Yang, Chong-Jen Yu
European Journal of Cancer.2020; 124: 110.     CrossRef
Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC
Xiaojie Fan, Xiaoxiao Wang, Meng Zhang, Huiyan Deng, Yueping Liu
Pathology - Research and Practice.2020; 216(1): 152783.     CrossRef
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
Sang Hoon Lee, Eun Young Kim, Arum Kim, Yoon Soo Chang
Cancer Biology & Therapy.2020; 21(8): 741.     CrossRef
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
Chi-Lu Chiang, Hsu-Ching Huang, Chia-I Shen, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu
Targeted Oncology.2020; 15(4): 503.     CrossRef
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
Shang-Gin Wu, Chi-Lu Chiang, Chien-Ying Liu, Chin-Chou Wang, Po-Lan Su, Te-Chun Hsia, Jin-Yuan Shih, Gee-Chen Chang
Frontiers in Oncology.2020;[Epub]     CrossRef
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Jianchun Duan, JiaChen Xu, Zhijie Wang, Hua Bai, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Jiefei Han, Di Wang, Yanhua Tian, Zhenlin Ya
Journal of Thoracic Oncology.2020; 15(12): 1857.     CrossRef
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients
Jung-Young Shin, Jeong-Oh Kim, Mi-Ran Lee, Seo Ree Kim, Kyongmin Sarah Beck, Jin Hyoung Kang
Cancers.2020; 12(12): 3579.     CrossRef
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Diagnostics.2020; 10(12): 1006.     CrossRef
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Research and Treatment.2019; 51(1): 408.     CrossRef
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
Yen‐Ting Lin, Jin‐Shing Chen, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Lin Hsu, Ching‐Yao Yang, Kuan‐Yu Chen, Jih‐Hsiang Lee, Zhong‐Zhe Lin, Jin‐Yuan Shih, James Chih‐Hsin Yang, Chong‐Jen Yu
International Journal of Cancer.2019; 144(11): 2887.     CrossRef
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
Targeted Oncology.2019; 14(4): 433.     CrossRef
Frecuencia de mutación T790M determinada por biopsia líquida en pacientes con cáncer pulmonar de células no pequeñas después de la progresión a inhibidores de tirosina cinasa contra EGFR en primera línea
Jorge Arturo Alatorre-Alexander, Patricio Santillán-Doherty, María del Rosario Flores-Soto, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid, Carla Paola Sánchez-Ríos
NCT Neumología y Cirugía de Tórax.2019; 78(4): 348.     CrossRef